{
    "nctId": "NCT00096434",
    "briefTitle": "Sorafenib in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Proportion of confirmed tumor responses, graded according to RECIST criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Clinical evidence of metastatic disease\n* Measurable disease\n* HER2-positive or -negative disease\n\n  * If HER2 gene amplified or strongly positive for HER2 by immunohistochemistry, patient must have had prior treatment containing trastuzumab (Herceptin\u00ae) unless contraindicated\n* Previously treated with anthracycline- and/or taxane-containing regimen in the neoadjuvant, adjuvant, or metastatic setting\n* Candidate for first- or second-line chemotherapy for metastatic disease\n* Core block or tumor slides of the primary or metastatic tumor available\n* No known brain metastases\n* Hormone receptor status:\n\n  * Not specified\n* Male or female\n* Performance status - ECOG 0-1\n* At least 3 months\n* WBC \u2265 3,000/mm\\^3\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 8.5 g/dL\n* No evidence of bleeding diathesis\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* AST \u2264 3 times ULN\n* Alkaline phosphatase \u2264 3 times ULN\n* PT normal\n* PTT normal\n* INR normal\n* Creatinine \u2264 1.5 times ULN\n* Calcium normal\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* No uncontrolled hypertension\n* No gastrointestinal tract disease that would preclude taking oral medication\n* No active peptic ulcer disease\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer\n* No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib or other study agents\n* No ongoing or active infection\n* No psychiatric illness or social situation that would preclude study participation\n* No other uncontrolled illness\n* See Disease Characteristics\n* More than 4 weeks since prior immunotherapy\n* No concurrent anticancer immunotherapy\n* No concurrent bevacizumab\n* See Disease Characteristics\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n* No more than 1 prior chemotherapy regimen for metastatic disease\n* No concurrent anticancer chemotherapy\n* Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting is allowed\n* No concurrent anticancer hormonal therapy\n* No prior radiotherapy to \u2265 25% of the bone marrow\n* More than 4 weeks since prior radiotherapy\n* More than 4 weeks since prior major surgery\n* No prior surgical procedure that would affect gastrointestinal absorption\n* No other concurrent drugs that target vascular endothelial growth factor (VEGF) or VEGF receptors\n* No concurrent antiretroviral therapy for HIV-positive patients\n* No other concurrent investigational agents\n* No other concurrent anticancer therapy\n* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs, including any of the following:\n\n  * Phenytoin\n  * Carbamazepine\n  * Phenobarbital\n* No concurrent rifampin\n* No concurrent Hypericum perforatum (St. John's wort)\n* No concurrent therapeutic anticoagulation\n\n  * Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial devices is allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}